Refractory AML: Clinical Trials

2 trials for Refractory AML, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Terminated 2

Follow Refractory AML: new trials by email Literature Review of Refractory AML trials Research Report on Refractory AML

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
CYNK-001 - Leukemia, Leukemia, Myeloid
Phase 1TerminatedCelularity Incorporated272020-03-122024-12-12
Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
GEM333 - Acute Myeloid Leukemia, Relapsed AML
Phase 1TerminatedAvenCell Europe GmbH362018-04-112022-09-29

Narrower conditions

Leukemia, Myeloid, Acute (2)  ·  Hematologic Diseases (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Neoplasm, Residual (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)

Broader conditions

Hemic and Lymphatic Diseases (2)  ·  Hematologic Diseases (1)  ·  Leukemia (1)  ·  Leukemia, Myeloid (1)  ·  Neoplasms (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms by Site (1)  ·  Neoplastic Processes (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Sponsors

AvenCell Europe GmbH (1)  ·  Celularity Incorporated (1)

Countries

Germany (1)  ·  United States (1)

Top investigators

Martin Wermke, MD (1)  ·  Sharmila Koppisetti, M.D (1)

NIH funding

2017 (1)